Celgene Corporation, makers of the oral, anti-myeloma chemotherapy agent, Revlimid, announced their 4th quarter and full-year financials this morning.
I’m not going to post all of the data here. But several parts of the report should interest my fellow multiple myeloma patients:
For the 4th quarter, Total Revenue Increased 38 Percent to $1.07 Billion
Global REVLIMID® Net Product Sales Increased 42 Percent to $708 Million
Global THALOMID® Net Product Sales of $91 Million
Here are figures for all four quarters of 2010:
Total Revenue Increased 34 Percent to $3.60 Billion
Global REVLIMID Net Product Sales Increased 45 Percent to $2.47 Billion
Global THALOMID Net Product Sales of $387 Million
That’s a lot of money! All I know is I’m a good customer–my insurance company paid over $84,000 for my Revlimid this year. Add in my co-pays and deductible of close to $2,000 and we can all agreed I did my part to support Celgene’s bottom line.
Do I think that is way too much to pay for my medication? Yes! But I’m alive and relatively well. Thanks Cigna! I paid my health insurance premiums and you stepped-up and paid as promised. Thanks, Celgene! Revlimid helped keep me alive for another year.
Enough said for now. Feel good and keep smiling! Pat